Atezolizumab in a oort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal Subtyps (CHANCE trial)

Atezolizumab in a oort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal Subtyps (CHANCE trial)

Background: Although immunotherapy with immune-checkpoint inhibitors (ICIs) has profoundly changed the therapeutic scenario in the treatment of advanced non-small cell lung cancer (NSCLC), trials of ICIs only enrolled NSCLC patients with common histology. Atezolizumab was approved by the United Stat...

Full description

Bibliographic Details
Main Authors: Francesco Gelsomino, Giuseppe Lamberti, Marcello Tiseo, Danilo Rocco, Giulia Pasello, Fabiana Letizia Cecere, Antonio Chella, Giada Grilli, Marcella Mandruzzato, Michele Tognetto, Marina Chiara Garassino, Marianna Macerelli, Silvia Novello, Fausto Roila, Ida Colantonio, Francesco Grossi, Michelangelo Fiorentino, Andrea Ardizzoni
Format: Article
Language:English
Published: SAGE Publishing 2020-07-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/1758835920915983

Internet

https://doi.org/10.1177/1758835920915983

Similar Items